# Invited abstracts

## Hamilton Fairley Award

- Melanoma therapy: from frustration to enthusiasm

## Joint Symposia

- ESMO-ASCO - Genomics in breast cancer: Opening new doors
- ESMO/CSCO - Building the clinical trials of the future
- ESMO-EACR - Targeted therapies: Promises, successes and failures
- ESMO-EANM-ESR - Imaging biomarkers in the era of targeted therapies
- ESMO-ESP - Molecular diagnostics for personalized cancer treatment
- ESMO-ESTRO - Innovative approaches to the treatment of brain metastases
- ESMO-JSMO - Recent advances in the treatment of GI tract and liver cancer in the EU and Japan
- ESMO-MASCC - Integration between medical oncology and supportive care: Two sides of the same coin
- ESMO DCTF-AORTIC-SLACOM-UICC-WHO - Independent and publicly funded research: A new global model

## Keynote sessions

- PI 3-kinase and cancer metabolism
- HPV biology and implications in gynecological malignancies
- The hallmarks of cancer revisited
- The characterization of lung cancer in multiple different diseases

## Special Symposia

- The impact of the cancer genome project and high-throughput analyses on personalised oncology: today and tomorrow
- Optimizing treatment in luminal breast cancer
- How to integrate new drugs in the current therapeutic landscape of metastatic triple negative breast cancer
- Molecular neuro-oncology: new avenues in diagnosis and treatment
- A paradigm shift in early drug development: individualizing to more patient benefit
- How can medical oncologists deal with the new wave of genetic information about their patients?
- Pursuing the NED condition in stage IV colorectal cancer
- From biology to treatment in advanced pancreatic and gastroesophageal cancer
- Re-inventing the medical treatment of advanced prostate cancer
- Molecular answers and targets on the horizon for the treatment of genitourinary malignancies
- Emerging diagnostic and therapeutic targets in gynecological cancers: from science to clinical practice
- Biologically based treatment in head and neck squamous cell carcinoma (HNSCC)
- Molecular targets in malignant lymphomas: from basic science to clinical practice

## Submitted abstracts

- Basic science
- Biomarkers
- Breast cancer, early stage
- Breast cancer, locally advanced and metastatic
- CNS tumors
- Developmental therapeutics
- Familial cancer and genetic syndromes
- Gastrointestinal tumors, colorectal
- Gastrointestinal tumors, non-colorectal
- Genitourinary tumors, non-prostate
- Genitourinary tumors, prostate
Gynecological cancers  ix319  Psycho-oncology  ix474
Head and neck cancer  ix334  Sarcoma  ix478
Hematological malignancies  ix348  Small cell lung cancer and other thoracic malignancies  ix492
Melanoma and other skin tumors  ix361  Supportive care  ix499
Neuroendocrine tumors and CUP  ix376  Translational research  ix528
New diagnostics  ix383  Tumor biology and pathology  ix541
Non-small cell lung cancer, early stage  ix385
Non-small cell lung cancer, locally advanced  ix389  Author index  ix546
Non-small cell lung cancer, metastatic  ix400  Subject index  ix586
Oncology and public health  ix447  Drug index  ix601
Palliative care  ix462  Translational research index  ix604
Prevention and screening  ix469

Note: Abstract suffixes
“IN” indicates an invited abstract
”O” indicates a submitted abstract accepted for oral presentation
”PD” indicates a submitted abstract accepted for poster discussion
”P” indicates a submitted abstract accepted for poster presentation
abstracts with no suffix have not been accepted for presentation at the Congress but are published in the Abstract Book.
“TiP” indicates a submitted abstract accepted for poster presentation, trial in progress
”PR” indicates a submitted abstract selected for press coverage